Vertical: HealthcareBase Year: 2017
Market Size (2017)
$251.58M
Projected (2023)
$327.55M
CAGR (2015–2023)
4.6%
Key Players
4+
Montelukast is a leukotriene receptor antagonist (LTRA) used to prevent wheezing, difficulty in breathing, chest tightness, and coughing caused by asthma. In addition, montelukast is indicated for the treatment of seasonal and perennial allergic rhinitis. Key factors driving market growth are worldwide rising prevalence of asthma, bronchospasm, allergic rhinitis, and urticaria, burgeoning pharmaceutical industry coupled with the increasing demand from active pharmaceutical ingredients (APIs) manufacturers, and montelukast patent expiration along with the increasing presence of generics. On the contrary, the presence of stringent regulatory policies and the high cost of manufacturing building blocks for active pharmaceutical ingredients are likely to hinder market growth during the forecast period.
The global montelukast intermediate market has been segmented based on application and region. The global montelukast intermediate market was valued at USD 3,699.61 thousands in 2017, and the market is estimated to grow at USD 4,794.76 thousands by 2023. In 2017, the Americas accounted for the largest market share of 40.02% with a market value of USD 1,480.70 thousands, followed by Europe with a market value of USD 1,041.67 thousands in 2017.
Based on application, the asthma segment accounted for the largest market share of 48.4% in 2017, with a market value of USD 1,789.65 thousands, which is projected to register a CAGR of 4.57% during the forecast period.
The Montelukast Intermediate Market market is projected to grow at a CAGR of 4.6% from 2015 to 2023.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansSubscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansMontelukast is a leukotriene receptor antagonist used to prevent wheezing, difficulty in breathing, chest tightness, and coughing caused by asthma and is also indicated for the treatment of bronchospasm, allergic rhinitis, urticaria, prophylaxis, hepatitis, cerebral spasm, and endotoxemia. Pharmaceutical intermediates are chemical compounds that are the building blocks used in the production of active pharmaceutical ingredients. In this study, the intermediate of montelukast, Benzoic acid, 2-[(3S)-3-[3-[(1E)-2-(7-chloro-2-quinolinyl)ethenyl]phenyl]-3-hydroxypropyl]-, methyl ester, CAS No. [181139-72-0] is thoroughly analyzed.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansSubscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansSubscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansThis report applies a rigorous multi-stage research process combining primary interviews, secondary data sources, and bottom-up market modelling to ensure accuracy and completeness across all segments and geographies.
Base Year
2017
Historical Period
2015 – 2016
Forecast Period
2018 – 2023
Primary Interviews
150+
Historical data (2015–2017) and forecast period (2017–2023)
Our research process spans primary interviews with industry stakeholders combined with comprehensive secondary data analysis, validated through triangulation across multiple independent sources.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansThe global montelukast intermediate market is a very niche market and a limited number of companies manufacture and market montelukast intermediates. Through extensive research, it is found that market players have adopted strategies such as product launches and collaborations with major players. On the basis of market study, we found some key players operating in this market which are VIVAN Life Sciences, P.G. Shah & Co., Manus Aktteva Biopharma LLP, Ortin Laboratories Limited, and others. The growth of these companies is majorly attributed to their high revenue growth, broad product portfolio, and wide global presence. The global montelukast intermediate market has a huge revenue base in major pharmaceutical markets including North America, Europe, and Asia-Pacific, with countries such as the US, France, the UK, India, and Africa being the major contributors
VIVAN Life Sciences is one of the leading players in the market with a strong customer base and market presence. The company has good research and development base and a strong product portfolio which provide a competitive advantage over other market players. Moreover, companies such as P.G. Shah & Co. are contributing to the growth of the market and catering to the needs of the customers by providing customization and establishing long term agreements with the customers. Manus Aktteva Biopharma LLP is a prominent player in the global montelukast intermediate market and is present in more than 50 countries covering major regions including Asia and Europe. Moreover, Ortin Laboratories Limited holds a significant market share in the global montelukast intermediate market and provides end to end services to customers in the market. The company also has its manufacturing unit which is WHO GMP Standards certified.
Many leading players are concentrated in the Asian region owing to the rising demand for asthma treatment, well-established markets, high healthcare expenditures, and numerous opportunities for growth. These companies have expanded their market in other regions as well. Major players in the market are investing a huge amount of money in research and development activities to launch better and cost-effective products in the montelukast intermediate market. They are also focusing on expanding their geographical boundaries by launching new products in emerging markets of developing countries.
Threat of New Entrants
The threat of new entrants is medium to high in the global montelukast intermediate market. Any contract development and manufacturing company trying to enter the market is required to accept or abide by the mandatory regulatory standards. However, the budget required for research and development of a product is low as compared to other industries. Montelukast intermediates are specialized and manufactured to be used in the manufacturing of pharmaceutical products. Moreover, the majority of the customers are using products of trusted sellers, and they are likely to prefer established brands over new market player due to quality concerns and to maintain the quality of final product, which does not comfort the new entrants to enter the market easily.
Bargaining Power of Suppliers
The suppliers in the global montelukast intermediate market are raw material manufacturers. There are various suppliers present in the global montelukast intermediate market. Switching cost of these suppliers is low due to intense competition, and also the raw materials required for the manufacturing of montelukast intermediate are easily used. Moreover, suppliers are likely to enter into long term partnerships with montelukast intermediate manufacturers. Due to the increasing research and development activities related to the montelukast and entry of major pharmaceutical companies in the market, a large number of customers are available.
Moreover, several suppliers are there to cater to the needs of the customers which lead to intense competition between the existing suppliers. However, low-quality products are likely to damage the quality of the final product, and it can cause adverse effects. Hence, customers are selective about suppliers. Due to this, the overall bargaining power of suppliers in the global montelukast intermediate market is low.
Bargaining Power of Buyers
The bargaining power of buyers is moderate in the global montelukast intermediate market. The market has a limited number of buyers and very few montelukast intermediate manufacturing companies to cater to the need of the buyers. However, the montelukast intermediate is specialized and play an important role in pharmaceutical product manufacturing, and the buyers of the montelukast intermediate are moderately inclined towards quality products manufactured by trusted companies. As the products are manufactured for the treatment of asthma, there are limited substitutes available in the market. Also, most of the buyers are pharmaceutical companies and research organizations; they are likely to enter into the long-term agreements with the montelukast intermediate manufacturers for uninterrupted supply. Moreover, they can exert pressure on the manufacturers due to the low switching cost and intense rivalry in the market, which is responsible for the increased bargaining power of buyers.
Threat of Substitutes
The threat of substitutes in the global montelukast intermediate market is low to moderate. Montelukast intermediates are used in the development and manufacturing of pharmaceutical products which are used for the treatment of asthma. There are limited options available in the market to serve the need of the customers and which eliminates the threat of substitute. However, the increasing research and development activities and demand for efficient intermediates are likely to provide new substitutes to the montelukast intermediate. Also, the high degree of switching cost decreases the threat of substitutes. The overall threat of substitutes in the global montelukast intermediate is low to moderate.
Intensity of Rivalry
The rivalry in the global montelukast intermediate market is moderate to high. The low degree of product differentiation and a limited number of customers increases the intensity of rivalry in the market. The market is growing with a prominent growth rate and likely to provide opportunities for major players to expand their geographical boundaries which will initiate cutthroat competition between major players to capture maximum market share in the emerging markets. Major players are trying to develop products under their own as a part of vertical integration. Players are engaged in developing a process to lower their manufacturing and logistics cost to increase profitability and to overcome the competition. Moreover, they are also developing advanced products for differentiating their brand from their competitors.
Market estimates by geography (2023)
InsightAmericas leads with $1.85B by 2023, while Asia Pacific is projected to grow fastest at a 5.4% CAGR.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription Plans| REGION | 2015 | 2017 | 2023 | CAGR | SHARE |
|---|---|---|---|---|---|
| Middle East and Africa | $227.75M | $276.17M | $327.55M | 4.6% | 7% |
| Americas | $1.36B | $1.60B | $1.85B | 4.0% | 39% |
| Asia Pacific | $824.59M | $1.03B | $1.26B | 5.4% | 26% |
| Europe | $941.15M | $1.14B | $1.36B | 4.7% | 28% |
| Total | $3.35B | $4.06B | $4.79B | 4.6% | 100% |
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansTotal Market Size
$327.55M
| APPLICATION | REVENUE ($B) | GROWTH RATE | MARKET PENETRATION |
|---|---|---|---|
| Asthma | $2.35B | 4.8% | 49% |
| Allergic Rhinitis | $1.15B | 5.0% | 24% |
| Bronchospasm | $747.13M | 4.6% | 16% |
| Urticaria | $329.63M | 4.0% | 7% |
| Others | $220.01M | 1.6% | 5% |
* Revenue projections based on 2025 estimates. Growth rates represent CAGR 2024–2030. Market penetration indicates current adoption rate within addressable market segments.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansSee plans for professionals or small and medium businesses.
Analytical insights on Montelukast Intermediate Market covering market dynamics, competitive landscape, and strategic outlook.
The Montelukast Intermediate Market market is projected to reach $327.55M by 2023, growing at 4.6% CAGR. The Asthma segment holds the largest share.
A patent is an exclusive sale right granted for an invention, product, or process that provides a new technical solution to a problem. In terms of the pharmaceutical market, the patent is being excised by various manufacturers to safeguard their products’ (drugs, APIs) sales. The European Patent Convention (EPC) requires all jurisdictions to give the European patent a term of 20 years from the actual date of applying. Likewise, in the US, the term of the patent is 20 years from the earliest filing date of the application on which the patent was granted. During this patent tenure, no other company (rather than the novel manufacturer) is allowed to market or manufacture the product, until there is a consent between two parties. Thus, the patent allows manufacturers to provide exclusive sales of their products in the absence of any competition for a limited period.
The montelukast intermediate market is entitled to witness rampant market growth during the forecast period from 2018 to 2023. Factors characterizing the market growth are worldwide rising prevalence of asthma, bronchospasm, allergic rhinitis, and urticaria, burgeoning pharmaceutical industry coupled with the increasing demand from API manufacturers, and montelukast patent expiration along with the increasing presence of generics. On the contrary, the presence of stringent regulatory policies and the high cost of manufacturing building blocks for active pharmaceutical ingredients (APIs) are likely to hinder market growth during the forecast period.
Research and development activities in montelukast intermediates by various organizations are expected to create ample opportunities for new market entrants and existing market players during the forecast period. Nanjing Wisdompharm Co., Ltd, a Chinese company focuses on technology innovations (in montelukast intermediates, pesticide formulation, and other chemicals), optimized management, and robust service system for its customers. In November 2018, IntelGenx Corp. (a Canadian oral drug delivery company engaged in the development and manufacturing of innovative pharmaceutical oral films based on its proprietary VersaFilm technology platform) commenced patient dosing in the Phase 2a study of montelukast VersaFilm in patients with mild to moderate Alzheimer’s disease (AD). This study enrolled around 70 subjects with mild to moderate Alzheimer’s disease to evaluate the safety, feasibility, tolerability, and efficacy of montelukast buccal film following the daily dosing for 26 weeks. Thus, these ongoing research activities in montelukast intermediates are expected to create promising avenues in the near future.
Stringent regulatory policies are imposed by various international healthcare authorities for the approval and use of pharmaceutical products. These authorities include US FDA (US), Medicines and Healthcare products Regulatory Agency (MHRA) (UK), Therapeutic Goods Administration (TGA) (Australia), Central Drugs Standard Control Organization (CDSCO) (India), Health Canada (Canada), Medicines Control Council (MCC) (South Africa), National Sanitary Surveillance Agency (ANVISA) (Brazil), European Medicines Agency (EMA) (European Union), State Food and Drug Administration (SFDA) (China), National Agency for Food and Drug Administration and Control (NAFDAC) (Nigeria), Medicines and Medical Devices Safety Authority (Medsafe) (New Zealand), Ministry of Health, Labor, and Welfare (MHLW) (Japan), Medicines Control Authority of Zimbabwe (MCAZ) (Zimbabwe), Swiss Agency for Therapeutic Products (Swissmedic) (Switzerland), Korea Food and Drug Administration (KFDA) (Korea), and Ministry of Health, Nutrition, and Indigenous Medicine (MoH) (Sri Lanka). These regulatory bodies ensure compliances in various legal and regulatory aspects of drugs. Government regulations lengthen the process for bringing new pharmaceuticals to the market thereby consuming time, which is anticipated to limit market growth over the forecast period.
Pricing is one of the most important factors for a product to survive in the market. The manufacturers should focus on the buying capacity of the consumer and manufacture cost-efficient products to achieve maximum profit or revenue or market share of the overall industry. Recent trends support that major companies are reducing the cost of their products to capture the maximum market share and to attract more customers. The reduced cost is enabling the large companies to attract the local market with their high quality which forces the small companies to reduce the price of their products to sustain the market.
Pricing Evolution
Pricing plays an important role in the healthcare industry. Montelukast intermediates are used in the manufacturing of montelukast API, and it is further converted into finished products. Pricing is the main concern when it comes to the sourcing of raw materials, and pharmaceutical companies are involved in various strategic partnerships and collaborations to cut the cost of raw materials. With the expiration of the montelukast patent in August 2012, the prices of montelukast intermediates went down with the entry of generic manufacturers. The pricing of montelukast intermediate depends on various factors including cost of production, competitors pricing, and profit margin.
Montelukast intermediate is used for manufacturing montelukast API which is an anti-asthmatic drug, used a long-term medication for asthma. The drug is regulated by regulatory bodies such as the US Food and Drug Administration (FDA), European Union (EU), and Therapeutic Goods Administration (TGA). The drug is manufactured under strict quality control complying with cGMP requirements and meeting various other global manufacturing standards. Some organizations such as the Regulatory Affairs Professional Society (RAPS), the Drug Information Association (DIA), and the Food and Drug Law Institute (FDLI) play a vital role in providing relevant information about the drug.
There are various factors which influenced the investment opportunities in the global montelukast intermediate market such as market potential, market growth, market competition, profitability, government regulation, demand for the products in the region, innovation, research & development, strategic collaboration, joint venture, accusation, licensing, franchising and cost of production.
Wantstats identified it could be a profitable investment opportunity for existing players and new entrants, to focus specifically on the development of innovative products as the demand for it is anticipated to increase in the coming years with increasing cases of asthma and related disorders. The existing players can enter into a strategic partnership with montelukast intermediate manufacturers and pharmaceutical companies to develop montelukast intermediates which are more efficient. Currently, a number of companies are engaged in developing therapeutic solutions for asthma for which they have adopted strategic partnership strategies. Moreover, major players in the market are investing a large amount of revenue for increasing manufacturing capacities and expansion of the montelukast intermediate manufacturing business.
Wantstats analysis revealed that the growing demand for advanced treatment options for asthma could pose huge opportunities for the companies in the market.
Near-term growth will likely concentrate in modular bioreactor lines and closed-system media workflows that shorten validation cycles while preserving batch traceability.
Partnerships between CDMOs and instrumentation vendors should accelerate standard datasets for comparability across sites, improving forecasting models used in capacity planning.
Longer horizon, organoid and microphysiological adoption may reshape segment mix; teams that invest early in assay interoperability and cloud QC hooks are better positioned to capture upside without fragmenting their analytics stack.
Profiles of 104 companies operating in the Montelukast Intermediate Market market, including revenue, employee count, and market positioning where available.
Showing 104 of 104 companies
Company Headquarters: Hyderabad, Telangana, India Founded: 1986 Workforce: 100+ Company Working: Ortin Laboratories Limited is involved in manufacturing and marketing pharmaceutical products and operates through business segments, namely, formulations, API intermediates, research and development, biotechnology, and merchant export trading. The company has its own WHO GMP Standards certified manufacturing unit for the production of raw materials and final products. It recently merged with M/s Vineet Laboratories Pvt. Ltd to expand its product portfolio and gained control over its drug intermediates manufacturing unit. It has a strong presence in India and caters to the needs of government and private customers.
Company Headquarters: Mumbai, Maharashtra, India Founded: 2010 Workforce: 50+ Company Working: VIVAN Life Sciences is into manufacturing, marketing, and distributing pharmaceutical intermediates and other raw materials to major players in the market. The company operates through business segments, namely, Standards, Deuterium Labelled Compounds, Metabolites, Impurities, Glucuronides, Chiral Standards, and Building Blocks. It also offers product synthesis and services to pharmaceutical and chemical companies all over the world. It has a strong client base and provides products and services to pharmaceutical and life sciences companies, contract research organizations (CRO), clinical research companies, specialty chemical companies, and various other companies which are involved in bio-availability and bio-equivalence studies at their clinical study centers.
Company Headquarters: Mumbai, India Founded: 1952 Company Working: P.G. Shah & Co. is a prominent player in the montelukast intermediate market. It is into sourcing and manufacturing of pharmaceutical raw materials for regulated and semi-regulated markets. The company operates through business segments, namely, APIs/bulk drugs, intermediates, and formulations. It has a strong research and development unit through which it develops quality products and provides end-to-end solutions to pharmaceutical companies. It has a manufacturing unit in India and a strong presence in the domestic market.
Company Headquarters: Ahmedabad, Gujarat, India Founded: 1997 Company Working: Manus Aktteva Biopharma LLP is a privately held company which is into manufacturing and marketing of pharmaceutical raw materials to pharmaceuticals, nutraceuticals, specialty chemicals, and biotechnology companies. It operates in business segments, namely, API, intermediates, and other products. It offers products and services to institutional and corporate customers and exports its products in more than 50 countries. The company has a strong network in China, India, and European countries. It is a trusted raw material supplier in the market and has the ISO 9001:2008 certification.
Coty is a fragrance-led global beauty company and, by its own description, one of the world's largest beauty groups, with FY2026 net revenues of USD 5.81bn split roughly two-thirds Prestige (licensed and owned luxury fragrance, prestige cosmetics and skincare — Burberry, Hugo Boss, Calvin Klein, Chloé, Marc Jacobs, Davidoff, Kylie Cosmetics, Gucci until mid-2027) and one-third Consumer Beauty (mass color cosmetics such as CoverGirl, Rimmel, Max Factor and Sally Hansen; mass fragrance; and Brazilian body care). Its core competitive asset is an end-to-end fragrance platform — licensing, innovation, ~81% in-house manufacturing and global prestige distribution — that has produced blockbuster franchises such as Burberry Goddess. After five years of deleveraging under Sue Nabi, Coty entered 2026 in a reset: revenue and margins are declining, the Gucci licence exits a year early, mass color and Brazil are under strategic review, and new interim leadership is executing a "Coty.Curated" focus-and-simplify framework with leverage of 3.4x. --- **Company's own description (paraphrased from FY2026 10-K, Item 1).** Coty describes itself as one of the world's largest beauty companies with an iconic brand portfolio across fragrance, color cosmetics, and skin and body care. It states that it is focused on leveraging its leadership position and capabilities in global fragrances to fuel expansion, strengthening its presence in a limited number of structurally profitable and growing categories, and prioritising growth channels such as e-commerce and Travel Retail. Under the Coty.Curated framework it emphasises fewer, bigger initiatives, marketing sufficiency, supply reliability, consumer advocacy, more productive innovation and portfolio choices, a return to market-share growth, and AI-powered, data-driven operations. It is also evaluating its central organisation, manufacturing and asset base to resize after the Gucci exit. **What the company does.** Coty designs, manufactures (≈81% in-house, ≈19% via third-party manufacturers in FY2026), markets and distributes beauty products. The essential oils in its fragrances are generally sourced from specialist fragrance houses; Coty owns the brand development, juice selection/briefing, bottle and packaging design, filling and assembly, marketing and commercial execution. Principal raw materials are essential oils, alcohols and specialty chemicals (10-K FY2026). **Business model and revenue model.** **Value-chain position.** Coty sits between ingredient suppliers (fragrance houses, alcohol and packaging suppliers) and retailers. Its economic moat lies in (i) licence portfolio scale in prestige fragrance, (ii) innovation and launch capability (brief-to-shelf), and (iii) owned manufacturing in the U.S., Europe and Brazil. It is structurally exposed to licensors (who own the trademarks) and to concentrated retailers (Sephora, Ulta, Douglas, Walmart, drug chains, travel-retail operators). **End markets.** Prestige fragrance (core), prestige cosmetics (Kylie Cosmetics, Marc Jacobs Beauty, Gucci Beauty until FY2027), prestige skincare (Lancaster, philosophy), mass color cosmetics, mass fragrance and mists, mass skin & body care (concentrated in Brazil). **Independent characterisation.** Coty is effectively two businesses with very different economics: a high-quality, licence-dependent prestige fragrance franchise generating ~20% adjusted EBITDA margins (Prestige FY2026 adjusted EBITDA margin 20.5% per Q4 FY2026 call), and a structurally challenged mass color cosmetics/Brazil business whose segment adjusted EBITDA margin collapsed to the low single digits in FY2026 (derived). The 2025–2026 strategic actions (Wella exit, Gucci monetisation, Consumer Beauty review) are converting Coty into a narrower fragrance pure-play with lower leverage but higher licence concentration.
Codexis is a Redwood City-based enzyme engineering company in the middle of a deliberate transition. It is moving from a diversified "protein engineering" platform company, whose revenue was historically dominated by custom biocatalysts for small-molecule drug manufacturing, toward a focused provider of enzymatic manufacturing solutions for oligonucleotide therapeutics, chiefly siRNA/RNAi. Its proprietary CodeEvolver® directed-evolution platform underpins two businesses. The first is a cash-generating but lumpy pharma biocatalysis franchise, anchored by long-standing relationships with Merck & Co. and other large pharmaceutical companies, which supports about 14 commercial products. The second is the pre-commercial ECO Synthesis® Manufacturing Platform, which aims to replace solid-phase phosphoramidite chemistry with enzymatic routes, together with a commercially launched dsRNA ligase. The company is a sub-$200 million market capitalization micro-cap and remains loss-making. It has about $80 million of pro forma liquidity, a $40 million term loan, and guidance for FY2026 revenue of $72–76 million. --- ### Company's own description (FY2025 10-K / standard press-release boilerplate, paraphrased) Codexis describes itself as a leading provider of enzymatic solutions for efficient, scalable therapeutics manufacturing. It discovers, develops and improves high-performance enzymes using its proprietary CodeEvolver® technology. According to the company, its enzymes address real-world problems in small-molecule pharmaceutical manufacturing and nucleic acid synthesis. Codexis is developing the ECO Synthesis® Manufacturing Platform to enable scaled manufacture of RNAi therapeutics through an enzymatic route. It says its enzymes can raise yields, cut energy use and waste, improve manufacturing efficiency, and increase sensitivity in genomic and diagnostic applications (Codexis Q4 FY2025 and Q2 FY2026 press releases). The FY2025 10-K states that headquarters is both the administrative centre and the centre of research, development and business operations, with limited internal manufacturing capacity. In-house manufacturing produces Codex® biocatalyst panels and kits, plus enzymes for customers' pilot-scale and clinical production. The ECO Synthesis Innovation Lab sits inside headquarters and is designed to supply non-GMP material in quantities that support customers' preclinical development. The company expects to partner with CDMOs for bulk GMP-grade siRNA production for clinical supply and beyond. ### Independent characterization Codexis is best understood as a technology-licensing and specialty-enzyme supplier whose economics depend on a small number of very large pharmaceutical relationships. In FY2025 a single customer accounted for about 51% of total revenue (FY2025 10-K, "Customers"). Given the $37.8 million Merck agreement recognised mainly in Q4 FY2025, that customer is almost certainly Merck. The business model has three monetization layers. The first layer is product revenue: sales of engineered enzymes (biocatalysts), pharmaceutical intermediates, Codex® biocatalyst screening panels and kits, and, increasingly, ligase and ECO enzyme supply. Product revenue is driven by customers' commercial manufacturing schedules and is therefore volatile quarter to quarter. Product gross margin has improved structurally, from 56% in FY2024 to 64% in FY2025 and 71–73% in Q1–Q2 FY2026. Management attributes this to a shift toward higher-margin products and the run-off of lower-margin legacy products. The second layer is research and development revenue: CodeEvolver platform licence fees, technology-transfer payments, milestone payments, feasibility and evaluation fees, and ECO Synthesis manufacturing services (for example, the low-seven-figure contract to supply 50 g of siRNA). In FY2025 R&D revenue exceeded product revenue for the first time in the period analysed ($44.4 million vs. $26.0 million). The main reason was the Merck technology transfer. The third layer is royalty and contingent consideration from out-licensed or divested assets. These include the Nestlé Health Science CDX-7108 sale (up to $45 million in milestones plus a single-digit royalty), the Aldevron HiCap RNA polymerase licence (milestones and royalties), and the Roche dsDNA ligase licence (upfront and technical milestones). These are largely back-ended and uncertain. **Value-chain position.** Codexis sits upstream of drug-substance manufacturing. It supplies process technology (enzymes and the know-how to use them) to innovator pharma companies, generic manufacturers and CDMOs, which then run the commercial processes. In the oligonucleotide chain it is trying to move one step downstream. Its planned ECO GMP Manufacturing Center would make siRNA material for preclinical and Phase 1 supply. This hybrid "tool supplier plus early-phase manufacturer" model is a new risk profile for the company. **Customer types:** large innovator pharma (Merck, plus historically Pfizer, GSK and Novartis); high-growth RNAi biotech innovators (unnamed counterparties in 2025–2026 agreements); CDMOs (Bachem, Nitto Denko Avecia, Axolabs); and life-science tools companies (Roche, Aldevron, seqWell). **End-markets served:** small-molecule API manufacturing (biocatalysis); oligonucleotide/RNAi therapeutic manufacturing; and, as a residual licensing stream, life-science tools and genomics reagents. ### Revenue model mix (FY2021–FY2025) *Sources: Q4 FY2022 press release (FY2021–FY2022 PAXLOVID figures); FY2023 10-K (product revenue); Q4 FY2023 press release (ex-PAXLOVID revenue of $62.0 million implies about $8.1 million PAXLOVID-related revenue in FY2023, largely the release of deferred Pfizer fees); Q4 FY2025 8-K Exhibit 99.1 (FY2024–FY2025). Shares are computed.*
Powering the world's best teams.
From next-gen startups to established enterprises.
Trusted by forward-thinking businesses
for data-driven intelligence
Co-Founder, Mojave Rail Fabrication Limited
This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job.
Manager, JavolVision
Thanks, I am so happy that we worked together. Maybe we still can work together in the future.
Sales Operations & Pricing Manager, Intel
Thanks. It's been a pleasure working with you, please use me as reference with any other Intel employees.
Sales Leader, Bamberg
We bought your "2025 report" in 2020. Everything is fine and very good.
Account and Business Manager, EFS-Holland BV
Thanks for sending the report it gives us a good global view of the Betaïne market.
Senior Retail Manager, LG Chem
We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.
Management Consultant, Level 21
I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.
Group Product Manager HVAC & Fire Protection GMA, Rockwool
I have been reading the first document or the study, the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!
R&D Director, Seojin
Thanks for your great support. Appreciate it. Well received report. It helps us to understand market well. We're planning other area of survey in the future, let's keep in touch.
Strategy & Business Development Director, Dogan Holding
We got the report in time, we really thank you for your support in this process. I also thank to all of your team as they did a great job.
Historical performance and future projections (2020–2030, USD Billion)
Market Size (USD Mn)
